Cantor Fitzgerald analyst Prakhar Agrawal downgraded Rapt Therapeutics to Neutral from Overweight, stating that there are “too many unknowns” after the company announced that the FDA has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon, RPT193, in atopic dermatitis and its Phase 2a trial in asthma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT:
- RAPT Therapeutics (NASDAQ:RAPT) Crashes after FDA Clinical Hold
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- Rapt Therapeutics initiated with an Outperform at Evercore ISI
- Wolfe starts Rapt at Outperform, sees multiple outperformance opportunities
